Journal of Drugs in Dermatology最新文献_第2页

Racial and Ethnic Representation in Atopic Dermatitis Clinical Trials. 特应性皮炎临床试验中的种族和民族代表性。

IF 1.5 4区医学

Journal of Drugs in Dermatology Pub Date : 2025-04-01 DOI: 10.36849/JDD.8705

Margaret Kabakova, Jennifer Y Wang, Paras Patel, Kayla Zafar, David Bitterman, Jared Jagdeo

{"title":"Racial and Ethnic Representation in Atopic Dermatitis Clinical Trials.","authors":"Margaret Kabakova, Jennifer Y Wang, Paras Patel, Kayla Zafar, David Bitterman, Jared Jagdeo","doi":"10.36849/JDD.8705","DOIUrl":"10.36849/JDD.8705","url":null,"abstract":"Atopic dermatitis (AD) is a chronic inflammatory skin disorder afflicting approximately 31.6 million people in the United States, with a disproportionate impact on racial and ethnic minorities who often experience greater disease severity. This study aims to analyze racial and ethnic representation in recent atopic dermatitis clinical trials. A search on clinicaltrials.gov identified 73 completed AD trials with results available from January 1, 2019, to May 13, 2024, and out of these, 68 trials involving 20,679 patients provided race and ethnicity data. Out of all clinical trial participants, 65.4% identified as White, 17.3% identified as Asian, 13.4% identified as Black or African American, 0.5% identified as American Indian or Alaskan Native, 0.4% identified as Native Hawaiian or Pacific Islander, and 1.3% identified as more than one race. Hispanic or Latino participants comprised 10.8% of the clinical trial population. This study highlights an increasing trend in the inclusion of African American/Black and Asian populations in AD clinical trials; however, Hispanic participants remain notably underrepresented despite increased ethnicity reporting. These disparities emphasize the necessity of diverse representation in AD clinical trials to ensure equitable treatment outcomes, especially given the higher disease prevalence in skin of color groups. Achieving equitable representation will improve the generalizability of trial results, enhance treatment access, and reduce health inequities. Greater inclusivity in AD clinical trials is crucial for understanding the safety, efficacy, and side effects of treatments across diverse populations and should be a cornerstone of dermatologic clinical research. J Drugs Dermatol. 2025;24(4):360-364. doi:10.36849/JDD.8705.","PeriodicalId":15566,"journal":{"name":"Journal of Drugs in Dermatology","volume":"24 4","pages":"360-364"},"PeriodicalIF":1.5,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143803609","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

INDIVIDUAL ARTICLE: USCOM V: A Practical Algorithm for the Prevention and Treatment of Cutaneous Side Effects of Hormonal Cancer Therapy. 个别文章：USCOM V：预防和治疗激素癌症治疗皮肤副作用的实用算法。

IF 1.5 4区医学

Journal of Drugs in Dermatology Pub Date : 2025-04-01 DOI: 10.36849/JDD.84821

Jennifer N Choi, Mario Lacouture, Anneke Andriessen, Alice Ho, Beth McLellan, Edith Mitchell, Jonathan Leventhal

{"title":"INDIVIDUAL ARTICLE: USCOM V: A Practical Algorithm for the Prevention and Treatment of Cutaneous Side Effects of Hormonal Cancer Therapy.","authors":"Jennifer N Choi, Mario Lacouture, Anneke Andriessen, Alice Ho, Beth McLellan, Edith Mitchell, Jonathan Leventhal","doi":"10.36849/JDD.84821","DOIUrl":"10.36849/JDD.84821","url":null,"abstract":"Introduction: In 2024, over 2 million patients will be diagnosed with cancer in the United States, with prostate cancer and breast cancer representing the leading diagnoses in men and women, respectively. Hormonal therapy is a mainstay treatment for hormone-dependent cancers but is associated with cutaneous adverse events. These include accelerated signs of aging, xerosis and pruritus, brittle nails, androgenic alopecia, and hirsutism. All clinicians involved in the care of these patients play an essential role in managing treatment-related cutaneous adverse events to minimize the burden on patients and improve their quality of life.Objectives: To develop a multidisciplinary, physician-developed algorithm to guide the care of patients who develop cutaneous hormonal therapy-related adverse events.Methods: A panel of advisors was selected, and a systematic literature review generated evidence to develop a treatment algorithm for managing cutaneous hormonal therapy-related adverse events via a modified Delphi process. The algorithm was developed based on the assembled evidence coupled with the panel's experience and opinion.Results: An algorithm that tailors the prevention and management of cutaneous hormonal therapy-related adverse events in cancer patients used the CTCAE v.5 grading of cancer therapy-related skin disorders. Suggested management recommendations supplement the algorithm.Conclusions: Prevention, recognition, and treatment of cutaneous hormonal therapy-related adverse events through the use of a physician-developed algorithm may limit treatment interruption, improve patient outcomes, and optimize the quality of life in patients on hormonal cancer therapy. J Drugs Dermatol. 2025;24:4(Suppl 2):s3-14.","PeriodicalId":15566,"journal":{"name":"Journal of Drugs in Dermatology","volume":"24 4","pages":"84821s3-84821s14"},"PeriodicalIF":1.5,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143803607","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A Retrospective Comparative Analysis of Cutaneous Adverse Reactions in GLP-1 Agonist Therapies. GLP-1激动剂治疗皮肤不良反应的回顾性比较分析。

IF 1.5 4区医学

Journal of Drugs in Dermatology Pub Date : 2025-04-01 DOI: 10.36849/JDD.8605

Sophia Daniel, Stephanie Waggett, Elliott Lyles, Pelin Sagut, Parisa Shamaei Zadeh, Anthony Marcelletti, Carol Stegura, Lara Wine Lee

{"title":"A Retrospective Comparative Analysis of Cutaneous Adverse Reactions in GLP-1 Agonist Therapies.","authors":"Sophia Daniel, Stephanie Waggett, Elliott Lyles, Pelin Sagut, Parisa Shamaei Zadeh, Anthony Marcelletti, Carol Stegura, Lara Wine Lee","doi":"10.36849/JDD.8605","DOIUrl":"10.36849/JDD.8605","url":null,"abstract":"Glucagon-like peptide-1 (GLP-1) agonists are used to treat type 2 diabetes mellitus (T2DM) and have recently gained approval and popularity for treating obesity and weight loss. There is a lack of data evaluating the types of reactions associated with this medication class, and this study aimed to characterize the types of cutaneous reactions seen across different GLP-1 agonists, and whether differences exist in reactions based on the reason for medication use. Through a retrospective review of cutaneous adverse events associated with semaglutide, dulaglutide, tirzepatide, lixisenatide, liraglutide, and exenatide in the FDA Adverse Event Reporting System, it was found that the 5 most common cutaneous reactions associated with GLP-1 agonists were eczematous, pruritus, drug eruptions, hyperhidrosis, and alopecia. Life-threatening cutaneous adverse events accounted for 2.17% of all cutaneous reactions, with no statistically significant differences observed between drug types. It was also found that GLP-1 agonist use for T2DM exhibited significantly higher rates of alopecia (P=0.000) and hyperhidrosis (P=0.000) in comparison to use for weight management. J Drugs Dermatol. 2025;24(4):413-415. doi:10.36849/JDD.8605.","PeriodicalId":15566,"journal":{"name":"Journal of Drugs in Dermatology","volume":"24 4","pages":"413-415"},"PeriodicalIF":1.5,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143803585","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

An Algorithm Integrating Acneceuticals into the Management of Acne Vulgaris. 一种将祛痘药物整合到寻常痤疮治疗中的算法。

IF 1.5 4区医学

Journal of Drugs in Dermatology Pub Date : 2025-04-01 DOI: 10.36849/JDD.8887

Hilary Baldwin, Cheri Frey, Adelaide Hebert, Edward Ted Lain, Todd Schlesinger

{"title":"An Algorithm Integrating Acneceuticals into the Management of Acne Vulgaris.","authors":"Hilary Baldwin, Cheri Frey, Adelaide Hebert, Edward Ted Lain, Todd Schlesinger","doi":"10.36849/JDD.8887","DOIUrl":"10.36849/JDD.8887","url":null,"abstract":"Background: Acne vulgaris is a common, chronic cutaneous disorder with numerous efficacious prescription and procedural treatments. Therapy, however, is hampered by medication intolerability and compromised by non-adherence. The use of acneceuticals is an effective way to improve patient outcomes.Methods: A panel of 5 dermatologists met for a consensus conference in October 2023 to identify a practical acne treatment and maintenance algorithm integrating acneceuticals with prescription medications and procedures.Results: The algorithm stratifies the use of acneceuticals first as monotherapy, adjunctive therapy, or maintenance therapy and then further diverges by skin phenotype (oily or dry/sensitive) and primary lesion morphology (comedonal or inflammatory). Finally, specific acneceuticals are recommended for each phenotypic description.Conclusion: The algorithm is intended to serve as a guideline for integrating active nonprescription skin care into prescription acne therapy, improving efficacy, tolerability, and adherence, resulting in superior patient outcomes. J Drugs Dermatol. 2025;24(4):376-380. doi:10.36849/JDD.8887.","PeriodicalId":15566,"journal":{"name":"Journal of Drugs in Dermatology","volume":"24 4","pages":"376-380"},"PeriodicalIF":1.5,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143803588","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Effects of a Moisturizer Containing Colloidal Oatmeal and Filaggrin Technology on Staphylococcus Species In Vitro. 含有胶体燕麦和 Filaggrin 技术的保湿霜对葡萄球菌体外培养的影响

IF 1.5 4区医学

Journal of Drugs in Dermatology Pub Date : 2025-04-01 DOI: 10.36849/JDD.8706

Cleo Whiting, Sara Abdel Azim, Nicolas Joly-Tonetti, Nadege Lachmann, Adam Friedman

{"title":"Effects of a Moisturizer Containing Colloidal Oatmeal and Filaggrin Technology on Staphylococcus Species In Vitro.","authors":"Cleo Whiting, Sara Abdel Azim, Nicolas Joly-Tonetti, Nadege Lachmann, Adam Friedman","doi":"10.36849/JDD.8706","DOIUrl":"10.36849/JDD.8706","url":null,"abstract":"The pathophysiology of atopic dermatitis (AD) is multifactorial, with genetic predisposition, environmental exposures, and dysbiosis of the skin microbiome all associated with disease activity. Colonization by Staphylococcus aureus (S. aureus) is specifically associated with AD, and modifying the skin microbiota through topical skincare products may play a role in AD management. A moisturizer containing colloidal oatmeal, a patented filaggrin technology, niacinamide, and tocopheryl acetate was assessed for its impact on the growth, biofilm formation, and bacterial mix adhesion of S. aureus and/or S. epidermidis on reconstructed human epidermis (RHE). Compared to control conditions, the bacterial growth and adhesion of S. aureus were decreased compared to S. epidermidis in the presence of the moisturizer. Additionally, the moisturizer did not significantly induce nor inhibit the formation of S. aureus biofilm relative to control. Overall, the moisturizer improved the growth ratio of Staphylococcus species, shifting the predominant species from pathogenic S. aureus to commensal S. epidermidis, which may be clinically beneficial in the management of AD. J Drugs Dermatol. 2025;24(4):416-418. doi:10.36849/JDD.8706&nbsp.","PeriodicalId":15566,"journal":{"name":"Journal of Drugs in Dermatology","volume":"24 4","pages":"416-418"},"PeriodicalIF":1.5,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143803602","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Improvement of Hailey-Hailey Disease Following Administration of Dupilumab. Dupilumab治疗后海莉病的改善

IF 1.5 4区医学

Journal of Drugs in Dermatology Pub Date : 2025-04-01 DOI: 10.36849/JDD.8060

Shravya Kichena, Jocelyn Carnicle, Mara Haseltine

引用次数: 0

Rituximab in the Treatment of Epidermolysis Bullosa Acquisita: A Systematic Review of the Literature. 利妥昔单抗治疗获得性大疱性表皮松解症：文献综述。

IF 1.5 4区医学

Journal of Drugs in Dermatology Pub Date : 2025-04-01 DOI: 10.36849/JDD.8483

Dimitra Xenopoulou, Justin W Marson, Falguni Asrani

{"title":"Rituximab in the Treatment of Epidermolysis Bullosa Acquisita: A Systematic Review of the Literature.","authors":"Dimitra Xenopoulou, Justin W Marson, Falguni Asrani","doi":"10.36849/JDD.8483","DOIUrl":"10.36849/JDD.8483","url":null,"abstract":"Epidermolysis bullosa acquisita (EBA) is a rare autoimmune disorder characterized by blistering of the skin and mucous membranes. Current pathophysiology implicates autoantibodies targeting type VII collagen, which serves as a crucial component of anchoring fibrils that attach the epidermis to the dermis. Management of EBA remains challenging and relies on a combination of anti-inflammatory, immunosuppressive, and immunomodulating agents. Despite treatment, EBA is often chronic and relapsing, thus significantly impacting patients' quality of life.13 In this report, we aimed to systematically review the literature to provide an overview of the effectiveness of pharmacotherapy in treating cases of EBA with rituximab (RTX), specifically. We explore the efficacy of RTX as immunomodulator monotherapy and also its use in combination with other agents. A total of 51 patients were included over 20 studies and all studies were either case reports/series or retrospective chart reviews. The most utilized adjuvant therapies were glucocorticoids (n = 29) in the forms of methylprednisolone (MP), prednisolone (PL), and prednisone (P). RTX use in combination with PL had the best overall result; this regimen resulted in 15.7% (n = 8) of patients having clinical remission (CR) and 9.8% (n = 5) having well-controlled (WC) disease. Notably, the review elucidated that 4 patients had treatment with RTX alone and 100% of them achieved either CR or partial remission/control (PR/C). Our review highlights the relative efficacy of RTX in combination therapy and as monotherapy for the treatment of this rare condition, but more powerful research in the form of randomized clinical trials is imperative in order to obtain a more comprehensive understanding of its utility in the treatment of EBA. J Drugs Dermatol. 2025;24(4):387-393. doi:10.36849/JDD.8483.","PeriodicalId":15566,"journal":{"name":"Journal of Drugs in Dermatology","volume":"24 4","pages":"387-393"},"PeriodicalIF":1.5,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143803611","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Improvement in Skin Moisturization and Lack of Barrier Damage Following Treatment With Clascoterone Cream 1. 使用Clascoterone霜后皮肤保湿性的改善和屏障损伤的减少

IF 1.5 4区医学

Journal of Drugs in Dermatology Pub Date : 2025-04-01 DOI: 10.36849/JDD.8774

Zoe D Draelos, Kizito Kyeremateng, Nicholas Squittieri

{"title":"Improvement in Skin Moisturization and Lack of Barrier Damage Following Treatment With Clascoterone Cream 1.","authors":"Zoe D Draelos, Kizito Kyeremateng, Nicholas Squittieri","doi":"10.36849/JDD.8774","DOIUrl":"10.36849/JDD.8774","url":null,"abstract":"Background: Topical medications commonly prescribed for the treatment of acne vulgaris may be limited by application-site dryness, which can result in skin barrier damage. This study aimed to evaluate the effects of clascoterone cream 1% on skin barrier properties in acne-prone individuals.Methods: Participants ≥18 years of age with acne-prone skin were enrolled in a single-center, split-face study and randomized to twice-daily treatment with clascoterone cream 1% (approximately 0.5 g) to the right or left side of the face for 2 weeks. The primary and secondary endpoints were the changes in corneometry reading and transepidermal water loss (TEWL), respectively, between treated and untreated sides at week 2. Tolerability was evaluated from the severity of dryness, erythema, scaling, irritation, tightness, stinging, itching, and burning for each side using a 5-point scale from 0 (none) to 4 (severe).Results: This study enrolled 50 participants (female, n = 38) with a mean ± standard deviation (SD) age of 31.1 ± 8.9 years. The mean ± SD corneometry reading was significantly higher for the treated vs untreated side at week 2 (131.3 ± 42.9 vs 113.9 ± 36.6; P<0.001). There was no difference in TEWL between treated and untreated sides at any time point assessed. All tolerability parameters evaluated were rated as absent or minimal through week 2 for both sides.Conclusion: Twice-daily treatment with clascoterone cream 1% for 2 weeks was associated with increased moisturization and maintenance of skin barrier function as assessed by corneometry and TEWL and was otherwise well tolerated. J Drugs Dermatol. 2025;24(4):397-402. doi:10.36849/JDD.8774.","PeriodicalId":15566,"journal":{"name":"Journal of Drugs in Dermatology","volume":"24 4","pages":"397-402"},"PeriodicalIF":1.5,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143803604","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Exploring the Therapeutic Potential of GLP-1 Agonists in Hidradenitis Suppurativa. 探索 GLP-1 激动剂对扁平苔藓的治疗潜力

IF 1.5 4区医学

Journal of Drugs in Dermatology Pub Date : 2025-04-01

Aarthi Parvathaneni, Emelie N McQuitty, Bailey Slawin, Sanjana Likki, T Austin Black, Nadeen Gonna, Rashid M Rashid

引用次数: 0

Off-Label Management Strategies for Generalized Granuloma Annulare: What's New? 广泛性环形肉芽肿的说明书外管理策略：有什么新进展？

IF 1.5 4区医学

Journal of Drugs in Dermatology Pub Date : 2025-04-01

Nikita Menta, Savanna I Vidal, Adam Friedman

引用次数: 0